期刊文献+

糖类抗原-125与人附睾蛋白4联合检测女性卵巢及子宫疾病的研究 被引量:7

Study on combined detection of HE4 and CA125 assay in female ovary and uterine diseases
下载PDF
导出
摘要 目的探讨糖类抗原-125(CA125)与人附睾蛋白4(HE4)联合检测女性卵巢及子宫疾病的价值。方法选择2010年10月至2013年12月在该院就诊的52例恶性卵巢肿瘤和118例良性卵巢肿瘤患者,检测患者的血清CA125与HE4水平。另选同期在该院进行健康体检的健康女性100例作为健康对照组,并绘制ROC曲线,计算AUC值,比较联合检测与单项检测的评价指标。结果良性卵巢肿瘤组血清HE4和CA125与健康对照组差异无统计学意义(P>0.05),而恶性卵巢肿瘤组血清HE4和CA125水平较健康对照组明显升高;恶性卵巢肿瘤组HE4检测阳性率(80.8%)明显高于CA125的阳性率(76.9%),差异有统计学意义(P<0.05);良性卵巢肿瘤组HE4检测阳性率与CA125差异无统计学意义(P>0.05);HE4检测的灵敏度、特异性、阳性预测值、阴性预测值均明显高于CA125,联合检测的灵敏度、特异性、阳性预测值高于单项检测,与HE4比较差异无统计学意义(P>0.05),与CA125比较差异有统计学意义(P<0.05),联合检测的灵敏度、AUC明显高于单项检测。结论 CA125与HE4联合检测女性卵巢及子宫疾病可提高检测的灵敏度,适用于女性健康体检的评估。 Objective To study the value of the combined detection of HE4 and CA125in female ovary and uterine diseases.Methods 52 cases of malignant ovarian tumors and 118 cases of benign ovarian tumors in our hospital from October 2010 to December 2013 were selected and detected the serum levels of CA125 and HE4.Contemporaneous 100 females of healthy physical examination were selected as the healthy control group.The ROC curve was drawn and AUC value was calculated.The values of the joint detection and single indicator detection were evaluated.Results The serum HE4 and CA125levels had no statistically significant difference between the benign ovarian tumor group and the healthy control group(P〉0.05);the serum HE4 and levels in the malignant ovarian tumor group were significantly higher than those in the healthy control group;the positive detection rate of HE4 in the malignant ovarian tumor group was significantly higher than that of CA125,the difference was statistically significant(80.8%vs.76.9%,P〈0.05);the positive detection rate in the benign ovarian tumor group had no statistical difference between CA125 and HE4(P〉0.05);the sensitivity,specificity,positive predictive value and negative predictive value of the HE4 detection were significantly higher than those of CA125,which of the combined detection were higher than those of the single detection,but which had no statistical difference compared with HE4(P〉0.05)and had statistical difference compared with HE4(P〈0.05).Conclusion The combined detection of HE4 and CA125can increase the detection sensitivity in female ovarian and uterine diseases and is suitable for the evaluation of women′s health check-up.
出处 《检验医学与临床》 CAS 2015年第13期1904-1906,共3页 Laboratory Medicine and Clinic
关键词 糖类抗原125 血清人附睾分泌蛋白4 卵巢及子宫疾病 carbohydrate antigen 125 serum human epididymis secretory protein 4 ovary and uterus disease
  • 相关文献

参考文献10

  • 1Kang S, Kim TJ, Nam BH, et al. Preoperative serum CA- 12 5 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis[J]. J Surg Oncol, 2010,101 (1): 13-17.
  • 2Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer[J]. Gyneeol Oneol, 2006,100 ( 1): 20-26.
  • 3孙静(综述),谢建华(审校).人附睾分泌蛋白与卵巢癌的关系[J].国际肿瘤学杂志,2010,37(3):222-225. 被引量:9
  • 4Zheng H, Gao Y. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease [J]. Int J Gynecol Cancer,2012,22(6): 1000-1005.
  • 5Moore RG, Brown AK, Miller MC, et al. The use of multi- ple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol On- col, 2008,108(2) : 402-408.
  • 6Skates SJ,Xu FJ, Yu YH, et al. Toward an optimal algo- rithm for ovarian cancer screening with longitudinal tumor markers[J]. Cancer, 1995,76 (10) : 2004-2010.
  • 7Stirling D, Evans DG, Pichert G,et al. Screening for famil- ial ovarian cancer:failure of current protocols to detect o- varian cancer at an early stage according to the interna- tional Federation of gynecology and obstetrics system[J]. J Clin Oncol,2005,23(24) :5588-5596.
  • 8欧健,张晓霞,王翠翠,王丽娜.血清人附睾蛋白4的检测及其在卵巢癌诊断中的意义[J].吉林大学学报(医学版),2010,36(3):543-545. 被引量:21
  • 9Drapkin R, Vonhorsten H H, Lin YF, et al. Human epidid- ymis protein 4 (HE4) is a secreted glyeoprotein that is overexpressed by serous and endometrioid ovarian carci- nomas[J]. Cancer Res,2005,65(6) :2162-2169.
  • 10Montagnana M, Lippi G, Ruzzenente O, et al. The utility of serum human epididymis protein 4 (HE4) in patient: with a pelvic mass[J]. J Clin Lab Anal,2009,23(5):331- 335.

二级参考文献6

共引文献27

同被引文献65

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部